AGP Executive Report
Last update: 10 hours agoVaccine & Pharma Watch: Valneva reported €64.0M in first-half 2026 product sales and reaffirmed full-year guidance of €135–150M, with a strong €121.5M cash position and a restructuring program expected to improve results later in 2026; regulators for its Lyme disease vaccine candidate are expected to make decisions within the next 12 months. Climate & Public Health: Tropical cities are struggling to cool down as urban heat islands trap daytime heat and release it at night, and with the 2026–2027 El Niño strengthening, record temperatures could hit hardest on vulnerable residents—especially where funding for shade, green roofs, light-colored surfaces, and other cooling steps is limited. Mauritius Drug Crisis: An arrest tied to a former junior minister’s family has reignited debate over political responsibility and safeguards around public resources, while editors urge Mauritius to keep the fight focused on rule of law rather than media-driven politics.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
